Replies to post #12978 on Bioelectronics Corp (BIEL)

[alexander77]

I think a lot of people are very positive, inlcuding the management team holding more than 60% of the O/S
http://www.sec.gov/cgi-bin/own-disp?CIK=0001320869&action=getissuer

The reimbusrement news is an enormous catalyst and if other European countries -which is more than likely- follow the examples of the Netherlands, it will be more important than FDA clearance.

Three institutions are holding BIEL shares as well:
http://finance.yahoo.com/q/mh?s=BIEL.PK+Major+Holders

and the latest updates:
"Canadian Print Campaign: ActiPatch will be featured in the printed March edition of Zoomer Magazine (http://www.zoomermag.com/) with a full page ad and the theme “Don’t Deal With It, Heal With It.” This print campaign is an early test for additional channels and messaging for the ActiPatch DRTV campaign. We will update our investors with the campaign results.
Canada Web Campaign: In addition to the print campaign, ActiPatch will have a banner campaign and e-mail blast that is targeted at people who identified themselves as having back pain.
UK Campaign Update: Our Allay tests in the UK are showing promising early results. The vast majority of the consumers signed up for the Loyalty Program, and they get their first device for free when they sign up using a credit card. The program includes automatic shipping and billing of three month’s supply, every three months. Additionally, the consumer can cancel the program anytime, even before the first paid shipment. Of the consumers who received the free trial, approximately 90% continued with the paid program. We are very excited about these results as this is a very high retention compared to other similar products/campaigns.
Clinical Studies: We are finalizing the protocol for the dental study, while discussing additional studies in Canada and the US. These additional studies will target C-sections and diabetic foot ulcers."

There is so much happening at BIEL, I wouldn't be surprised if it would hit .050 soon.